Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study  by Goregaonkar, Arvind et al.
CURRENT THERAPEUTIC RESEARCH
VOLUME 70, NUMBER I, FEBRUARY 2009
Comparative Assessment of the Effectiveness and
Tolerability of Lornoxicam 8 mg BID and Diclofenac
50 mg TID in Adult Indian Patients With Osteoarthritis
of the Hip or Knee: A 4-Week, Double-Blind,
Randomized, Comparative, Multicenter Study
Arvind Goregaonkar, MS(Ortho)l; K.]. Mathiazhagan, MS(Ortho)2;
Ravindra R. Shah, MS(Ortho)3; Paramjeet Singh Kapoor, MS(Ortho)4;
Praveen Taneja, MS(Ortho)5; Akhilesh Sharma, MD6; Chandrashekhar Bolmall, MD6;
and Vidyagauri P. Baliga, PhD6
1Department of Orthopedics, Lokmanya Tilak Municipal Medical College and General
Hospital, Sion, Mumbai, India; 2Department of Orthopedic Surgery, M R Hospital,
Chennai, India; 3Department of Orthopedics, Khwaja Banda Nawaz Institute of Medical
Sciences, Gulbarga, India; 4Grecian Super-Specialty Hospital, Mohali, India;
5RGS Healthcare Pvt. Ltd, Mohali, India; and 6Medical Services Department, Glenmark
Pharmaceuticals Ltd, Mumbai, India
ABSTRACT
BACKGROUND: Reports of cardiovascular adverse events (AEs) associated with
the use of cyclooxygenase-2 inhibitors for the treatment of osteoarthritis (OA) have
prompted the quest for a better-tolerated NSAID.
OBJECTIVE: The aim of this study was to compare the effectiveness and tolera-
bility of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients
with OA of the hip or knee.
METHODS: This 4-week, double-blind, randomized, comparative, multicenter
study was undertaken to compare orallornoxicam and diclofenac in patients with OA.
Patients who met the selection criteria were enrolled consecutively from the outpa-
tient clinics of each of the participating hospitals in India. Participants completed the
Western Ontario and McMasters Individual Osteoarthritis Index (WOMAC-OA),
WOMAC Composite Index (WOMAC-CI) (for pain, stiffness, and physical func-
tion), and a 10-cm visual analog scale (VAS) (0-10 where 0 = no pain and 10 =
worst possible pain or severe or excruciating pain) at each study visit (weeks 0 [base-
line}, 2, and 4 [or at early termination}). Patients' and physicians' global assessments
of arthritis control were measured at each study visit when laboratory and clinical
AEs were also monitored. The primary end points were the WOMAC-OA, the
WOMAC-CI, and VAS scores for pain among the patients who completed the
study.
RESULTS: Of the 273 patients (159 men, 114 women; mean [SD} age,
44.73 [l0.72} years; range, 28-68 years) enrolled in the study, 13 (7 in the lornoxi-
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cam group and 6 in the diclofenac group) were lost to follow-up and their effectiveness
and tolerability results were not included in the study analysis. Over the 4-week study
period, both drugs provided significant (P < 0.05) sustained relief of OA symptoms
compared with baseline. Compared with baseline, the mean pain score (WOMAC-CI)
decreased 90.6% (13.88 [4.47) vs 1.30 [1.49}; P < 0.05) in the lornoxicam group and
88.9% (14.15 [4.56} vs 1.57 [1.49}; P < 0.05) in the diclofenac group after 4 weeks
of treatment. After 4 weeks of treatment, the VAS pain score decreased from base-
line 83.1% (8.04 [2.70} vs 1.36 [1.43}; P < 0.05) in the lornoxicam group and
79.3% (7.98 [2.98} vs 1.65 [1.47}; P < 0.05) in the diclofenac group. Compared
with baseline, the improvement rated at 2 weeks was not significantly different
between the 2 groups. Lornoxicam and diclofenac were well tolerated. The rate of
mild to moderate adverse gastrointestinal events was not significantly different in
the lornoxicam group compared with the diclofenac group (14.6% vs 18.4%). Simi-
larly, overall tolerability between the 2 groups was not significantly different.
None of the patients experienced cardiovascular AEs (eg, edema or increased blood
pressure).
CONCLUSION: The results of the present study suggest that lornoxicam was
comparable to diclofenac in effectiveness and tolerability after 4 weeks of treatment in
these adult Indian patients with OA of the hip or knee who completed the study. (Curr
Ther Res Clin Exp. 2009;70:56-68) © 2009 Excerpta Medica Inc.
KEY WORDS: lornoxicam, diclofenac, osteoarthritis, India.
INTRODUCTION
Although nonpharmacologic interventions are the cornerstone of osteoarthritis (OA)
management, analgesics are an important component of treatment during the symp-
tomatic periods of the disease. In this respect, current practice guidelines advocate the
use of an analgesic (acetaminophen) or an NSAID administered either systemically or
topically as first- or second-line drug therapy. 1 However, in view of the cardiovascular
adverse events (AEs) associated with the use of cyclooxygenase (COX)-2 inhibitors, a
well-tolerated NSAID is needed.
Lornoxicam is an NSAID of the oxicam class with a similar mechanism of action as
other oxicams. An in vitro study suggested that lornoxicam is 100 times more potent
than tenoxicam as a COX inhibitor. 2 Its analgesic potency is 12 and 10 times greater
than that of piroxicam and tenoxicam, respectively. 3 Published clinical trials have
documented the effectiveness of lornoxicam as a potent analgesic with excellent anti-
inflammatory properties in a range of painful and/or inflammatory conditions, includ-
ing OA.3-5 Lornoxicam has been marketed recently in India, and based on a literature
search of MEDLINE (English language; January 2006-June 2008; search terms,
lornoxicam, diclofenac, Indians, osteoarthritis), there were no comparative studies in the
Indian population.
Therefore, the present study was undertaken to compare the effectiveness and tolera-
bility of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients
with OA of the hip or knee.
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PATIENTS AND METHODS
STUDY DESIGN
This double-blind, randomized, comparative study was conducted in 5 hospitals
across India. The ethical review committees of each participating center (Lokmanya
Tilak Municipal Medical College and General Hospital, M R Hospital, Khwaja Banda
Nawaz Institute of Medical Sciences, and Grecian Super-Specialty Hospital) approved
the study protocol and the informed consent forms. The study was conducted in ac-
cordance with the ethical standards for the treatment of patients as outlined in the
Declaration of Helsinki.
All eligible patients were provided oral explanations about the nature of the study
and about the study drugs. An information sheet was provided in a language under-
stood by each patient before study inclusion. Written informed consent was obtained
from each of the participants before study initiation.
I NCLUSION AND EXCLUSION CRITERIA
Patients were enrolled consecutively from the outpatient clinics of each of the par-
ticipating hospitals. The flowchart in Figure 1 depicts the patient enrollment scheme.
Patients who were eligible for the study were Indian men and women aged 30 to
70 years with a diagnosis of OA of the knee or hip confirmed by clinical and diagnos-
tic radiographic criteria. Participants were required to have a diagnosis of functional
Patients screened
(N = 273)
I
Randomization
Lornoxicam Diclofenac
(n = 137) (n = 136)
Lost to follow-up Lost to follow-up
(n = 7) (n = 6)
Completed study Completed study
(n = 130) (n = 130)
Figure 1. Patient disposition in the study.
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class I, II, or III according to the American College of Rheumatology Criteria,6,7
which was confirmed by the investigators. Only those patients willing to comply with
study procedures and requirements were enrolled in the study. Finally, patients were
enrolled if their baseline assessment of arthritis pain was >4 on a visual analog scale
(VAS) (0-10 where 0 = no pain and 10 = worst possible pain, or severe or excruciating
pain) and if both the patients' and physicians' assessment of arthritis control was poor
or very poor.
Patients were excluded from the study if they had a concurrent arthritic condition
that might confound or interfere with the evaluation of effectiveness (determined
through medical history, laboratory tests, physical examination, and responses to a
questionnaire). These included inflammatory arthritis, gout, episodes of acute mono-
articular arthritis clinically consistent with pseudogout, Paget's disease affecting the
study joint, a history of septic arthritis or intra-articular fracture of the study joint,
osteochondritis desiccans or osteonecrosis of the study joint, Wilson's disease, hemo-
chromatosis, ochronosis, or primary osteochondromatosis. Other concurrent medical
conditions that resulted in exclusion included severe cardiac, hepatic, renal, or cere-
brovascular disease; malignancy; chronic inadequately controlled systemic diseases
(eg, diabetes, hypertension, collagen disorders); or any other serious illness. Pregnant
and nursing women were also excluded from the study, as were those with sympto-
matic bursitis or acute joint trauma of the index knee and/or hip. Patients with condi-
tions predisposing them to gastrointestinal dysfunction (eg, a history of peptic ulcer,
upper gastrointestinal disease, or ulcerative colitis; smoking; concurrent corticosteroid
use; alcohol abuse) were not included in the study. Patients were also excluded if they
had a history of bleeding tendencies, cirrhosis, or esophageal varices, or hypersensitivi-
ty or allergy to NSAIDs, other COX-2 inhibitors, or sulfonamides. Patients with
preexisting asthma, those who would require concomitant drug treatment (eg, low-
dose aspirin, warfarin, antiepileptic drugs, fluconazole [inhibitor of cytochrome P450
(CYP) 2C9/3A4}, or ketoconazole [a known inhibitor of CYP3A4}) were also exclud-
ed. Patients who had participated in a new drug study in the past 3 months and im-
munocompromised patients were excluded from the study. Patients with any other
condition that, in the opinion of the investigator, might confound the study results or
pose a risk to the patient (eg, comorbid conditions for which NSAIDs or paracetamol
were contraindicated) were also excluded. The decision to exclude individuals from the
study was based on their responses to a questionnaire regarding their health status.
At the screening visit, patients who satisfied the inclusion criteria were required to
discontinue their current NSAID treatment. There was a 1-week washout period be-
fore the baseline arthritis assessment. No concurrent treatment other than physio-
therapy was allowed during the study. Systemic or topical NSAIDs, intra-articular
steroids, disease-modifYing drugs, and other experimental forms of treatment were
strictly prohibited.
TREATMENT
Patients were randomly assigned to treatment with lornoxicam 8 mg BID or
diclofenac 50 mg TID for 4 weeks. The randomization list was computer-generated
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in a 1: 1 ratio. To maintain blinding of the investigators and patients, the study drugs
were packed separately as morning, afternoon, and nighttime doses and were placed
in identical sealed containers. Because the recommended dosing regimen is BID for
lornoxicam and TID for diclofenac, an additional dummy tablet similar in appearance,
taste, and smell to the lornoxicam tablet was provided to maintain blinding in the
lornoxicam group.8,9 The randomization code was to be broken only after the analyses
were completed.
At the end of the study period, patients were advised to continue the study drugs
or to switch to another NSAID at the discretion of the investigator.
Rescue medication in the form of acetaminophen 500-mg tablets (maximum dos-
age, 2.5 g/d) was permitted for intractable pain in the study joint during the washout
period and during the course of the study when pain was not adequately controlled by
the study medication. The number of acetaminophen tablets consumed by the pa-
tients was recorded at each visit.
EFFICACY ASSESSMENTS
The primary objective of the present study was to assess the effectiveness and tol-
erability of lornoxicam 8 mg BID and diclofenac 50 mg TID in the treatment of pa-
tients with OA. The investigators performed clinical evaluations at outpatient visits
at weeks 0 (baseline), 2, and 4 (or at early termination) after the administration of the
first dose of the study drugs. The primary end points were the Western Ontario and
McMasters Individual Osteoarthritis Index (WOMAC-OA), the WOMAC Composite
Index (WOMAC-CI) (for pain, stiffness, and physical function), and VAS scores (for
pain). The VAS was presented as a 100-mm or 10-cm horizontal line on which the
pain intensity was represented by a point between the extremes of 0 and 10 (where
o = no pain and 10 = worst possible pain, or severe or excruciating pain). The patient
rated his or her pain on this line while the graduations were hidden. According to the
patient's representations, pain was graded and compared before, during, and after
treatment. The severity was reported as follows: 0 = no pain, 1 to 3 = mild pain, 4 to
6 = moderate pain, and 7 to 10 = severe pain.
At each visit, patients completed the WOMAC-OA and the WOMAC-CI, a self-
administered questionnaire, consisting of 24 questions (5 regarding pain, 2 regarding
stiffness, and 17 regarding physical function) scored on a 5-point scale (where 0 =
none and 4 = extreme). Patients' and physicians' global assessment of arthritis control
using a 5-point scale (where 0 = very good and 4 = poor) was measured at each visit.
The incidence of patient withdrawal and the time to patient withdrawal due to lack
of study drug effectiveness were monitored.
SAFETY AND TOLERABILITY ASSESSMENTS
Patients were monitored for laboratory and clinical AEs at each visit. All AEs or
unexpected events were recorded in the case record forms. Patients were queried by
the investigators for any AEs between study visits. The nature, date of onset, and
duration of AEs were recorded. All investigator-reported clinical AEs were recorded
at each study visit and evaluated by the investigator for intensity, seriousness, and
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relationship to the study medication. Severity of an AE was graded by an investigator
as follows: 1 = mild (awareness of sign or symptom but easily tolerated); 2 = moderate
(discomfort enough to cause interference with usual activity); or 3 = severe (incapaci-
tating, with inability to work or do usual activity). AEs that occurred within 7 days of
the last study drug dose and serious AEs that occurred within 30 days of the last study
drug dose were included in the safety analyses.
Compliance was monitored throughout the study using a count of the unused
medication at each visit.
STATISTICAL ANALYSIS
The sample size calculation assumed a difference of;;,4 between the scores of the
2 groups with lornoxicam and diclofenac. The change from baseline to end point for
the lornoxicam group and the diclofenac group was 47.3 and 43.3, respectively, with
a standard deviation of 13, 80% power, and an a of 0.05. The primary analysis popu-
lation was per protocol (PP) population. Patients had to complete the study with a
permissible dropout rate of 20% to ensure that 260 completer patients (130/group)
would be available in the PP population.
Efficacy variables (changes in scores for pain, stiffness, physical function, WOMAC-CI,
VAS, and patients' and physicians' global response to therapy) were analyzed using the
Kruskal-Wallis test. The laboratory investigations were analyzed using analysis of
variance. Statistical analysis was performed using SPSS version 10.0 (SPSS Inc., Chicago,
Illinois). All statistical tests for differences were 2-tailed with a = 0.05. P < 0.05 was
considered statistically significant. Data were expressed as mean (SD).
RESULTS
A total of 273 patients (159 men, 114 women; mean [SD} age, 44.73 [l0.72} years; range,
28-68 years) were enrolled in the study (Table I). One hundred thirty-seven patients re-
ceived lornoxicam 8 mg BID and 136 received diclofenac 50 mg TID. Seven patients
(5.1%) in the lornoxicam group and 6 (4.4%) in the diclofenac group were considered to
be dropouts (ie, patients who received the initial dose, but did not return for the subse-
quent follow-up visits, despite repeated reminders from medical social workers associated
with the institutions). Because these patients were considered to be lost to follow-up, their
data were not included in the effectiveness and tolerability assessment.
The baseline demographic data of the study patients is shown in Table 1. The
2 treatment groups were comparable in age, sex, and weight. All vital signs (tempera-
ture, pulse rate, respiratory rate, and blood pressure) were within the normal range at
baseline. After 4 weeks of treatment, there were no clinically relevant or statistically
significant changes in the vital signs. No significant changes were observed in weight
for both groups.
A total of 260 patients were included in the analysis: 130 patients received lornoxi-
cam and 130 patients received diclofenac. A majority of the patients in both groups
had a history of OA of the knee, while the remaining patients had a history of OA of
the hip. A similar number of patients in both groups had a history of comorbid condi-
tions (eg, gastritis, hypertension, diabetes) (Table 1).
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Table I. Baseline demographic and clinical characteristics of adult Indian patients with
osteoarthritis (OA) of the knee or hip treated with lornoxicam or diclofenac
(N = 273).*
Characteristic
Age, y
Mean (SD)
Range
Weight, kg
Mean (SD)
Range
Sex, no. (%)
Male
Female
Patients with previous NSAID therapy, no. (%)
History of OA, no. (%)
Knee
Hip
Duration of arthritis, y
Mean
Range
Comorbid condition, no. (%)
Gastritis
Cardiac disorder
Hypertension
Asthma
Diabetes
Respiratory tract infection
Urinary tract infection
Lornoxicam Group Diclofenac Group
(n = 137) (n = 136)
51.37 (12.38) 44.09 (9.06)
31-68 28-67
59.83 (10.02) 59.82 (9.03)
45-92 46-90
76 (55.5) 83 (61.0)
61 (44.5) 53 (39.0)
24 (17.5) 27 (19.9)
115 (83.9) 119 (87.5)
22 (16.1) 17 (12.5)
2.67 3.01
0.9-3.6 0.8-4.0
8 (23.5) 7 (17.1)
6 (17.6) 4 (9.8)
5 (14.7) 9 (22.0)
4 (11.8) 5 (12.2)
4 (11.8) 7 (17.1)
4 (11.8) 3 (7.3)
3 (8.8) 6 (14.6)
*No significant between-group differences were found.
At baseline, the mean (SD) pain score (WOMAC-CI) was 13.88 (4.47) in the lor-
noxicam group and 14.15 (4.56) in the diclofenac group. After 4 weeks of treatment,
the reduction in pain was significant in both the lornoxicam group (90.6%) and the
diclofenac group (88.9%; both, P < 0.05). The reduction in pain was not statistically
different between groups (Table II).
The mean (SD) baseline VAS score was similar in the lornoxicam (8.04 [2.70})
and diclofenac (7.98 [2 .98}) groups. After week 4, the VAS scores were significantly
reduced from baseline in the lornoxicam and the diclofenac groups (83.1 % and
79.3%, respectively; both, P < 0.05). There was no statistically significant between-
group difference (Table II).
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Table II. Changes in pain and visual analog scale (VAS) scores by treatment group in
adult Indian patients with osteoarthritis of the knee or hip treated with lornoxi-
cam or diclofenac.* Values are mean (SO).
Pain Scoret VAS Pain Scorer
Week Lornoxicam Diclofenac Lornoxicam Diclofenac
o (Baseline) 13.88 (4.47) 14.15 (4.56) 8.04 (2.70) 7.98 (2.98)
2 4.77 (2.18)§ 5.66 (2.21)§ 3.80 (2.08)§ 4.20 (2.12)§
4 1.30 (1.49)§ 1.57 (1.49)§ 1.36 (1.43)§ 1.65 (1.47)§
*No significant between-group differences were found.
tpatients were asked to indicate the level of knee pain (0-4, where 0 = none and 4 = extreme) associ-
ated with walking, stair climbing, nighttime, rest, and bearing weight.
rMeasured on a 10-mm scale of 0 to 10 (where 0 = no pain and 10 = worst possible pain or severe
or excruciating pain).
§p < 0.05 versus baseline.
At baseline, the mean (SD) stiffness score was 5.25 (2.25) in the lornoxicam group
and 5.47 (2.44) in the diclofenac group. After 4 weeks of treatment, stiffness de-
creased significantly in the lornoxicam and diclofenac groups (80.0% and 78.1 %,
respectively; both, P < 0.05 vs baseline). There was no statistically significant between-
group difference (Table III).
The mean (SD) physical function score was 37.96 (9.28) and 38.64 (9.44) in the
lornoxicam and diclofenac groups, respectively, at baseline. After 4 weeks of treat-
ment, the physical function score was reduced significantly in both groups (80.4%
and 76.5%, respectively; both, P < 0.05 vs baseline). There was no statistically sig-
nificant between-group difference (Table III).
Table III. Changes in stiffness and physical function scores by treatment group in adult
Indian patients with osteoarthritis of the knee or hip treated with lornoxicam
or diclofenac.* Values are mean (SO).
Stiffnesst Physical Functionr
Week Lornoxicam Diclofenac Lornoxicam Diclofenac
o (Baseline) 5.25 (2.25) 5.47 (2.44) 37.96 (9.28) 38.64 (9.44)
2 1.77 (1.78)§ 2.16 (1.92)§ 23.97 (7.77)§ 26.86 (8.06)§
4 1.05 (1.50)§ 1.20 (1.50)§ 7.43 (2.94)t 9.08 (3.36)§
*No significant between-group differences were found.
t Measured on a scale of 0 to 4 for the following: morning stiffness and stiffness later in the day.
r Measured on a scale of 0 to 5 for the following: descending stairs, ascending stairs, rising from sitting,
standing, bending to floor, walking on flat surface, getting injout of car, shopping, putting on socks,
rising from bed, taking off socks, lying in bed, getting injout of bath, sitting, getting onjoff toilet, heavy
domestic duties, and light domestic duties.
§ p < 0.05 versus baseline.
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At baseline, the mean (SD) total WOMAC-OA score in the lornoxicam and di-
clofenac groups was 57.09 (14.28) and 54.53 (14.60), respectively. After 4 weeks of
treatment, the score was significantly reduced in both groups (82.9% and 79.4%,
respectively; both, P < 0.05 vs baseline). There was no statistically significant between-
group difference (Table IV).
Improvement rated at 2 weeks was not statistically different between the 2 groups.
In the lornoxicam group, the mean stiffness score was reduced 66.3% (5.25 [2.25}
vs 1.77 [1.78}), physical function score was reduced 36.9% (37.96 [9.28} vs
23.97 [7.77}), VAS score was reduced 52.7% (8.04 [2.70} vs 3.80 [2.08}), and total
WOMAC score was reduced 46.6% (57.09 [l4.28} vs 30.51 [l0.19}) (all, P <
0.05 vs baseline). In the diclofenac group, the stiffness score was reduced 60.5 %
(5.47 [2.44} vs 2.16 [1.92}), physical function score was reduced 30.5% (38.64 [9.44}
vs 26.86 [8.06}), VAS score was reduced 47.4% (7.98 [2.98} vs 4.20 [2.12}), and total
WOMAC score was reduced 39.0% (54.53 [l4.60} vs 33.25 [9.63}) (all, P < 0.05 vs
baseline) (Tables II-IV).
Based on the global assessment of treatment by the patients after 4 weeks of treat-
ment, 75.0% of patients in the lornoxicam group rated the response to treatment as
good to very good compared with 78.3% of patients in the diclofenac group (P = NS).
Similarly, 4.2% ofpatients in the lornoxicam group rated the response as poor compared
with 4.3% of patients in the diclofenac group (P = NS) (Figure 2).
Based on the global assessment of treatment by the investigators after 4 weeks of
treatment, 79.2% of patients in the lornoxicam group were rated as having a good to
very good response compared with 82.6% in the diclofenac group (P = NS). Similarly,
4.2% of patients in the lornoxicam group and 4.3% in the diclofenac group were rated
as having a poor response (P = NS) (Figure 3).
Twenty of the 137 patients (14.6%) receiving lornoxicam experienced 27 AEs and
25 of the 136 patients (18.4%) receiving diclofenac had 32 AEs. The most commonly
Table IV. Total Western Ontario and McMasters Individual Osteoarthri-
tis Index (WOMAC-OA)* score by treatment group in adult
Indian patients with osteoarthritis of the knee or hip treated
with lornoxicam or diclofenac.t Values are mean (SO).
WOMAC-OA Index Score
Week
o (Baseline)
2
4
Lornoxicam
(n = 137)
57.09 (14.28)
30.51 (10.19)1'
9.78 (4.03)1'
Diclofenac
(n = 136)
54.53 (14.60)
33.25 (9.63)1'
11.22 (4.03)1'
*Divided into 3 dimensions: pain, stiffness, and physical function. Each dimen-
sion has several items and each item is graded according to the Likert scale on
a scale of 0 to 4. There were 24 total items in the WOMAC-OA.
t No significant between-group differences were found.
l' p < 0.05 versus baseline.
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Figure 2. Global assessment of 4 weeks of treatment by adult Indian patients with osteo-
arthritis of the knee or hip treated with lornoxicam (n = 137) or diclofenac
(n = 136). No significant between-group differences were observed.
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Figure 3. Physicians' global assessment of 4 weeks of treatment in adult Indian patients
with osteoarthritis of the knee or hip treated with lornoxicam (n = 137) or di-
clofenac (n = 136). No significant between-group differences were observed.
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reported AEs in both groups were gastritis, nausea and vomiting, headache, and ab-
dominal pain. The intensity of all AEs was rated as mild to moderate and disappeared
with continued therapy (Table V). Both lornoxicam and diclofenac were well tolerated.
None of the patients experienced any cardiovascular AEs (eg, edema or increased
blood pressure).
No clinically relevant alterations in any of the laboratory findings were observed.
None of the patients in either group required rescue analgesics (ie, acetaminophen).
All patients were considered to be compliant throughout the course of the study.
DISCUSSION
Pain and impaired mobility result in decreased quality of life for patients with rheu-
matic diseases. The aim of treatment is rapid, efficient analgesia to achieve the best pos-
sible result for these patients. Lornoxicam is a strong analgesic and anti-inflammatory
NSAID with balanced COX-l/COX-2 inhibition and excellent tolerability.4
OA affects millions of people worldwide. Because there is no cure for OA, drug
treatment is the primary form of management. This can be achieved with analgesics
and anti-inflammatory drugs, such as NSAIDs.3
After 2 weeks of treatment, improvements in mean stiffness, physical function, pain,
and total WOMAC Index scores were not significantly different between the 2 groups.
In a randomized, double-blind, clinical study with lornoxicam 4 mg TID and 8 mg
BID, both doses were as effective as diclofenac 50 mg TID for the treatment of pa-
tients with OA of the hip and/or knee for ::0-3 months before the start of the study.s
The percentage of patients showing improvements in disease activity (~46%) and
pain intensity (42%--48%) was similar in all 3 groups. No significant difference in
the tolerability of all 3 regimens was found. The results of the present study are con-
Table V. Occurrence of adverse events (AEs) by treatment group in
adult Indian patients with osteoarthritis of the knee or hip
treated with lornoxicam or diclofenac (N = 273).* Data are
no. unless otherwise specified.
AEs
Gastritis
Abdominal pain
Nausea/vomiting
Headache
Drowsiness
Dizziness
Diarrhea
Total AEs
Patients experiencing AEs, no. (%)
Lornoxicam
(n = 137)*
7
4
6
6
2
1
1
27
20 (14.6)
Diclofenac
(n = 136)
11
7
5
4
2
2
1
32
25 (18.4)
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sistent with the findings of this study.s Diclofenac sodium, a nonselective COX in-
hibitor, and etoricoxib, a selective COX-2 inhibitor, has been widely used in treating
patients with OA.lO The chronic use of diclofenac sodium has been reported to be as-
sociated with gastrointestinal AEs.l1
In another double-blind, multicenter, placebo-controlled study in patients with
OA, lornoxicam (<;12 mg/d for 4 weeks) appeared to be better tolerated than would
be expected for a drug of this class.3 The authors suggested that lornoxicam was likely
to be a useful addition to the drugs available for the treatment of OA. Pain relief scores
were significantly better than placebo during treatment with lornoxicam 8 and
12 mg daily. Lornoxicam was well tolerated at both 8 and 12 mg daily. Similar obser-
vations were made with 8 mg doses of lornoxicam in the present study.
Lornoxicam has a better gastrointestinal tolerability profile than other oxicams.
This has been attributed to lornoxicam's shorter half-life (~4 hours) compared with
>24 hours for the other oxicams. 6 Eighteen healthy male volunteers received lornoxi-
cam 8 mg BID or naproxen 500 mg BID administered orally for two 7-day dosing
periods. Upper endoscopy was performed by 2 independent investigators at the begin-
ning and end of each dosing regimen. Lornoxicam was associated with significantly
less mucosal injury than naproxen in the stomach/duodenal bulb and in the mid/distal
duodenum. 12 In the present study, gastrointestinal AEs were reported by a similar
number of patients in the lornoxicam and diclofenac groups.
The present study had some limitations. It was undertaken in a restricted group of
patients due to several exclusion criteria, preventing extrapolation of the results to the
general population. Furthermore, the study was of short duration and only those pa-
tients who completed the study were included in the efficacy and safety analysis.
CONCLUSION
The results of the present study suggest that lornoxicam was comparable to diclofenac
in effectiveness and tolerability after 4 weeks of treatment in these adult Indian pa-
tients with OA of the hip or knee who completed the study.
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